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Stockholm, Sweden, 3) Department of Infectious Diseases, Landspitali University Hospital and 4) Faculty of Medicine, University of Iceland, Reykjavik, IcelandAbstractStaphylococcus aureus is a leading cause of infective endocarditis. Little has been published on the outcome and epidemiology of S. aureus
endocarditis (SAE) in the twenty-ﬁrst century. Our aim was to evaluate the short-term and long-term outcome of SAE in Stockholm,
Sweden, and assess its incidence over time. Patients treated for SAE from January 2004 through December 2013 were retrospectively
identiﬁed at the Karolinska University Hospital. Clinical data were obtained from medical records and the diagnosis was veriﬁed
according to the modiﬁed Duke criteria. Of 245 SAE cases, 152 (62%) were left-sided and 120 (49%) occurred in intravenous drug users.
The calculated incidence in Stockholm County was 1.56/100 000 person-years, increasing from 1.28 in 2004–08 to 1.82/100 000 person-
years in 2009–13 (p 0.002). In-hospital and 1-year mortality rates were 9.0% (22/245) and 19.5% (46/236), respectively. Age (OR 1.06
per year) and female sex (OR 3.0) were independently associated with in-hospital mortality in multivariate analysis. Involvement of the
central nervous system (CNS) was observed in 30 (12%) patients, and valvular surgery was performed during hospitalization in 37 (15%).
In left-sided endocarditis the strongest predictors for surgery were severe valvular insufﬁciency (OR 8.9), lower age (OR 1.07 per year)
and no intravenous drug use (OR 10.7), and for CNS involvement lower age (OR 1.04 per year). In conclusion we noted low mortality,
low CNS complication rate, and low valvular surgery frequency associated with SAE in our setting. The incidence was high and increased
over time. The study provides an update on the outcome and epidemiology of SAE in the twenty-ﬁrst century.
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E-mail: hilmir.asgeirsson@karolinska.seIntroductionStaphylococcus aureus has become the leading cause of infective
endocarditis (IE) in many regions of the world [1–5]. Staphy-
lococcus aureus endocarditis (SAE) is associated with severe
morbidity and mortality. The case fatality ratio has generallyMicrobiol Infect 2015; 21: 772–778
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.04.014been reported to be 20–30%, central nervous system (CNS)
complications are common, and cardiac valve surgery is often
needed [5–10]. Earlier studies on SAE have, however, rarely
included large number of patients [5–12], and few have focused
on patients diagnosed in the twenty-ﬁrst century [6]. Predictors
of mortality in SAE have been identiﬁed [5,6,9,12], but factors
associated with valvular surgery and CNS involvement have
rarely been assessed speciﬁcally for SAE.
The objective of the present study was to evaluate the short-
term and long-term mortality, and changes in incidence over
time of SAE in Stockholm, Sweden, during 2004–13. Risk fac-
tors for mortality and CNS involvement, and factors associated
with valvular heart surgery were assessed.ious Diseases. Published by Elsevier Ltd. All rights reserved
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Stockholm County has 2.2 million inhabitants (1.7 million adults
18 years). The Karolinska University Hospital serves as a
tertiary referral centre for the entire population, providing
secondary health care to part of it. It includes the only thoracic
surgery department in the region. Hence, the great majority of
patients with suspected IE in Stockholm are admitted to Kar-
olinska University Hospital.
Individuals treated for SAE at the Department of Infectious
Diseases (ID) at Karolinska University Hospital from January
2004 through December 2013 were included. A retrospective
search was carried out in the records of the department for
diagnostic codes representing IE according to the 10th revision
of International Classiﬁcation of Diseases. The medical records
were reviewed and microbiological data were obtained to
identify cases with IE caused by S. aureus. Clinical data and
echocardiography reports were reviewed and the diagnosis of
IE was veriﬁed according to the modiﬁed Duke criteria [13].
Data on population statistics were retrieved from Statistics
Sweden. The regional Ethical Review Board in Stockholm
approved the study, not requiring obtaining informed consent
on an individual basis because of its retrospective nature.
Deﬁnitions
An episode of IE was deﬁned as deﬁnite or possible according to
the modiﬁed Duke criteria [13]. IE was deﬁned as right-sided if
it only involved structures on the heart’s right side (tricuspid
valve, pulmonic valve, pacemaker or implantable-cardioverter-
deﬁbrillator leads). SAE episodes involving structures on the
heart’s left side, or involving both the right and left sides were
classiﬁed as left-sided. A new episode within 90 days after
completing treatment for SAE was considered to be a relapse
and was not counted as a separate episode. Blood culture
systems used were BACTEC™ (Becton Dickinson and Com-
pany, Sparks, MD, USA) during 2004–07 and BacT/ALERT®
(bioMérieux, Marcy l’Etoile, France) during 2004–13.
An infection was considered nosocomial if signs or symp-
toms of IE presented more than 48 h after admission, or less
than 48 h after hospital discharge after a minimum of 2 days
hospitalization. Infection was also deﬁned as nosocomial if
related to haemodialysis. Otherwise it was considered to be a
community-onset episode. A healthcare-associated community-
onset infection was deﬁned by the identiﬁcation of at least one
of the following risk factors: 1) admittance to hospital for two
or more days in the 90 days before the SAE, 2) attendance at a
specialized hospital clinic or emergency department in the 30
days before SAE, 3) having an intravascular catheter at the timeClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyof infection, or 4) developing SAE directly following a proce-
dure in another healthcare setting (modiﬁcations from Fried-
man et al. [14]). CNS involvement or complication, was deﬁned
as CNS embolization, intra-cerebral haemorrhage or CNS
infection. In-hospital mortality was deﬁned as all-cause death
during admittance at an acute care hospital, also if the patient
had been transferred to another hospital and died there.
Statistical analysis
Description of data are given by number of observations, me-
dians, ranges and quartiles. The Pearson’s chi-square test, or
Fisher’s exact test when needed, were used for comparing cat-
egorical data. The Mann–Whitney U test was used to compare
continuous data between groups. Time trend in incidence rates
was tested by the chi-square trend test. Survival data are dis-
played by Kaplan–Meier curves and groups were compared by
the log-rank test. Multivariate logistic regression was performed
to calculate the contribution of different variables to mortality,
CNS complications and in-hospital cardiac surgery, with the
likelihood ratio test being used. Variables were considered for
the models in a stepwise fashion, but the ﬁnal selection of vari-
ables was also based on clinical judgement. Level of signiﬁcance
was set at 0.05. For processing the data the JMP®8.0.2 statistical
software from SAS Institute Inc. (Cary, NC, USA) was used.ResultsPopulation
A total of 673 medical records containing an IE diagnosis at the
Department of ID at Karolinska University Hospital were
identiﬁed. In 255 episodes S. aureus was the aetiological path-
ogen. Ten episodes were excluded, ﬁve with rejected IE diag-
nosis by the authors, and ﬁve were relapses within 90 days of a
previous SAE episode. Hence, 245 SAE episodes were seen in
222 individuals (13 had two episodes each and ﬁve had three
episodes each). Of these 227 (93%) were deﬁnite IE cases and
18 (7%) were possible IE cases. Polymicrobial aetiology was
present in seven (3%) cases. Echocardiography was performed
in 244 (99.6%) episodes, by the trans-oesophageal route in 208
(85%) and solely trans-thoracic in 36 (15%). In 150 (61%) pa-
tients a cardiac murmur was described, new in 46 (19%, in-
formation lacking for seven patients). The valve involvement of
the 245 SAE episodes is depicted in Table 1. The clinical
characteristics of SAE are shown in Table 2, with a comparison
between left-sided and right-sided episodes.
Incidence
During the ﬁrst half of the study period 96 SAE episodes were
seen and 149 in the second half. By using the whole referraland Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 772–778
TABLE 1. Valve characteristics of 245 Staphylococcus aureus
endocarditis episodes
Characteristic n (%)
Location
Left-sided a 152 (62)
Right-sided 91 (37)
Unknown 2 (1)
Prosthetic valve IE 28 (11)
Number of valves involved b
One valve 193 (79)
Two valves 30 (12)
Three valves 3 (1)
Valves involved c
Aortic 79 (32)
Mitral 87 (36)
Tricuspid 87 (36)
Pulmonic 7 (3)
Pacemaker/ICD leads 13 (5)
Other 1 (0.4)
Unknown 9 (4)
Data are number (%) of episodes. ICD, implantable cardioverter deﬁbrillator; IE,
infective endocarditis.
aIncluding 19 cases with bilateral involvement.
bUnknown in nine episodes, solely pacemaker/ICD leads in ten patients.
cTotal exceeds 245 as each episode can involve more than one valve.
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Stockholm County was calculated to be 1.56/100 000 person-
years, increasing from 1.28 in 2004–08 to 1.82/100 000
person-years in 2009–13 (p 0.002). This translates into 47.7
SAE episodes/10 000 admissions at the Department of ID inTABLE 2. Characteristics of Staphylococcus aureus endocarditis by
Characteristics Left-sided (n [ 152) R
Age, median years (IQR) 60.3 (48–74) 38
Male sex 117 (77) 54
Mode of acquisition
Nosocomial 18 (12) 4
Healthcare-associated 24 (16) 3
Community-acquired 110 (72) 84
Underlying conditions
Intravenous drug use 42 (28) 77
Predisposing heart disease a 56 (37) 6
Previous IE 24 (16) 18
Pacemaker / ICD 12 (8) 11
Haemodialysis 12 (8) 3
Insulin-dependent diabetes mellitus 15 (10) 4
Immunosuppression b 16 (11) 7
Polymicrobial aetiology 5 (3) 2
Methicillin resistance 4 (3) 2
Treatment
In-hospital cardiac surgery 37 (24) 0
Days to surgery, median (IQR) 9 (5.5–19) —
Days admitted, median (IQR) c 36 (28–46) 30
Outcome/complications
Severe valvular insufﬁciency d 36 (24) 16
Myocardial abscess e 18 (12) 1
CNS involvement 30 (20) 0
Total embolism f 48 (32) 63
ICU admission, non-postoperative 34 (22) 17
Relapse of bacteraemia g 2 (1) 5
30-day mortality 13 (9) 2
In-hospital mortality 20 (13) 2
1-year mortality h 40 (27) 6
Data are number (%) of episodes unless otherwise indicated. CNS, central nervous system;
endocarditis; IQR, interquartile range; n, number of episodes; ns, not signiﬁcant.
aProsthetic valve, congenital malformations (excluding atrial septal defect), valvular dysfuncti
bHuman immunodeﬁciency virus infection (13), immunosuppressive therapy (10), myelodysp
cInformation missing in 11 transferred cases.
dGrade 3 or 4 by echocardiography (on a 4-grade scale).
eIdentiﬁed by echocardiography.
fPulmonary embolism, cerebral embolism, or other systemic embolism.
gExcluding 15 patients who died within 30 days.
hExcluding eight cases with a re-infection within 1 year, one with incomplete follow up.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect2004–08 and 76.3 episodes/10 000 admissions in 2009–13
(p < 0.001). Forty-nine (51%) patients were referred from
other hospitals in 2009–13 compared with 68 (46%) in
2004–08 (p 0.41). No changes were observed during the
period in the valvular location or mode of acquisition of SAE
(data not shown).
Mortality
Fifteen (6.1%) patients died within 30 days, and 22 (9.0%)
died during the acute admission (Table 2). More speciﬁcally
the in-hospital mortality was 17% (19/110 episodes) among
non-addicts with left-sided SAE. For those who died during
the admission, the median time to death was 25.5 days (range
5–61 days). Table 3 depicts factors associated with in-
hospital mortality as analysed by multivariate logistic regres-
sion. The 1-year mortality was 19.5% (46/236 episodes,
excluding eight with a re-infection within 1 year and one with
incomplete follow up). Independent risk factors associated
with 1-year mortality were higher age (OR 1.04 per year,
95% CI 1.02–1.07, p < 0.0001) and left-sided disease (OR
2.62, 95% CI 1.05–7.53, p 0.04) (see Supplementary material,
Table S1). Fig. 1 depicts survival curves after SAE according
to age.location
ight-sided (n [ 91) p All episodes (n [ 245)
.0 (29–50) <0.0001 53.4 (38–69)
(59) 0.004 173 (71)
(4) 0.05 23 (9)
(3) 0.002 27 (11)
(93) 0.0006 195 (80)
(85) <0.0001 120 (49)
(7) <0.0001 62 (25)
(20) ns 43 (18)
(12) ns 23 (9)
(3) ns 16 (7)
(4) ns 20 (8)
(8) ns 24 (10)
(2) ns 7 (3)
(2) ns 6 (2)
(0) <0.0001 37 (15)
— 9 (5.5–19)
(27–36) 0.003 33 (28–42)
(18) 0.26 52 (21)
(1) 0.003 19 (8)
(0) <0.0001 30 (12)
(69) <0.0001 111 (46)
(19) ns 51 (21)
(6) ns 7 (3)
(2) 0.046 15 (6)
(2) 0.004 22 (9)
(7) 0.0001 46 (19)
ICD, implantable cardioverter deﬁbrillator; ICU, intensive care unit; IE, infective
on, hypertrophic cardiomyopathy.
lastic syndrome (1), splenectomised (1).
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 772–778
TABLE 3. Factors associated with in-hospital mortality in Staphylococcus aureus endocarditis
Variable
Univariate analysis Multivariate analysis
Died in hospital (n [ 22) Survived (n [ 223) p Odds ratio (95% CI)a p
Age, median years (IQR) 65.7 (56–85) 50.5 (35–67) <0.0001 1.06 (1.02–1.09) b 0.0005
Female sex 9 (41) 63 (28) 0.21 2.95 (1.06–8.16) 0.04
IE in 2009–13 12 (55) 137 (61) 0.53
Nosocomial IE 1 (5) 22 (10) 0.41
Prosthetic valve IE 5 (23) 23 (10) 0.08 2.08 (0.59–6.48) 0.24
Right-sided IE c 2 (9) 89 (40) 0.004 0.37 (0.05–1.60) 0.20
Valves involved d
Aortic 7 (32) 72 (33) 0.94
Mitral 13 (59) 74 (33) 0.02
Tricuspid 2 (9) 85 (40) 0.004
Severe valvular insufﬁciency e 5 (23) 47 (21) 0.87
Myocardial abscess f 2 (9) 17 (8) 0.81
Underlying conditions
Intravenous drug use 3 (14) 117 (52) 0.0005
Predisposing heart disease g 7 (32) 55 (25) 0.46
Previous IE 3 (14) 40 (18) 0.61
Immunosuppression h 3 (14) 21 (9) 0.52
Insulin-dependent diabetes 2 (1) 18 (8) 0.87
Methicillin resistance 0 (0) 6 (3) 0.44
Combination antibiotic therapy i 9 (41) 64 (29) 0.23
In-hospital cardiac surgery 5 (23) 32 (14) 0.30 2.34 (0.62–8.12) 0.20
Data are number (%) of episodes unless otherwise indicated. IE, infective endocarditis; IQR, interquartile range; n, number of episodes in analysis.
aOdds ratios for the association between selected variables and in-hospital mortality in the multivariate analysis. Variables with odds ratios reported were included in the ﬁnal
multivariate logistic regression model.
bOdds ratio presented per 1-year increase in age.
cUnknown side in two episodes.
dEach episode can involve more than one valve.
eGrade 3 or 4 by echocardiography (on a 4-grade scale).
fIdentiﬁed by echocardiography.
gProsthetic valve, congenital malformations (excluding atrial septal defect), valvular dysfunction, hypertrophic cardiomyopathy.
hHuman immunodeﬁciency virus infection (13), immunosuppressive therapy (10), myelodysplastic syndrome (1), splenectomised (1).
iCombination therapy including an aminoglycoside or rifampicin for 4 days.
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Thirty (12%) patients had a CNS complication in association
with the SAE (cerebral imaging was performed in 76 (31%)
episodes). Six had intra-cerebral bleeding, two had meningitis,
and the others had cerebral emboli with neurological symptoms
of various degrees. Five out of 30 (17%) patients died during the
admission. Factors independently associated with CNS
involvement in left-sided SAE were lower age (OR 1.04 per
year, 95% CI 1.01–1.07), not being an intravenous drug user
(OR 3.8, 95% CI 1.2–14.2), and mitral valve involvement (OR
2.7, 95% CI 1.1–7.3) (Table 4).FIG. 1. Survival after Staphylococcus aureus endocarditis according to
age, <55 or 55 years (p < 0.0001, log-rank test).
Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyTreatment
Cardiac surgery was performed before hospital discharge in 37
(15%) patients. All operations were performed on patients with
left-sided IE, ﬁve of which had bilateral disease and also needed
tricuspid valve surgery. In left-sided IE, independent predictors
of having cardiac surgery were lower age (OR 1.07 per year,
95% CI 1.03–1.12), no active IVDU (OR 10.7, 95% CI
2.6–52.2), community-onset (OR 9.3, 95% CI 1.5–115.1), se-
vere valvular insufﬁciency (OR 8.9, 95% CI 3.2–26.9),
myocardial abscess (OR 4.1, 95% CI 1.02–16.7), and intensive
care unit admission (OR 3.1, 95% CI 1.1–9.0) (see Supple-
mentary material, Table S2).
Cloxacillin (usually given as 3 g every 6 h) was the principal
treatment in 186 (76%) episodes, second- and third-generation
cephalosporins in 41 (17%), and vancomycin in 12 (5%). The
median treatment duration with intravenous antibiotics was 32
days (range 7–72 days, excluding 22 deaths and ﬁve lacking
information).
DiscussionThis study includes a large number of SAE cases from a single
northern European university clinic, with a high admission rate
of patients with IVDU and a low rate of methicillin-resistant
S. aureus strains. It highlights factors associated with mortality,
CNS complications and the need for valvular surgery in SAE.and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 772–778
TABLE 4. Factors associated with central nervous system complications in left-sided Staphylococcus aureus endocarditis
Variable
Univariate analysis Multivariate analysis
CNS event (n [ 30) No CNS event (n [ 122) p Odds ratio (95% CI) a p
Age, median years (IQR) 53.9 (43–68) 62.3 (51–75) 0.02 0.96 (0.93–0.99) b 0.007
Male sex 20 (67) 97 (80) 0.13
IE in 2009-13 17 (57) 79 (60) 0.75
Nosocomial IE 3 (10) 15 (12) 0.73
Prosthetic valve IE 7 (23) 19 (16) 0.31
Valves involved c
Aortic 13 (43) 66 (54) 0.29
Mitral 21 (70) 66 (54) 0.11 2.66 (1.06–7.28) 0.04
Underlying conditions
Intravenous drug use 9 (30) 33 (27) 0.75 0.26 (0.07–0.86) 0.03
Predisposing heart disease d 12 (40) 44 (36) 0.69
Previous IE 8 (27) 16 (13) 0.07 3.21 (1.00–10.43) 0.05
Immunosuppression e 4 (13) 12 (10) 0.58
Insulin-dependent diabetes 1 (3) 14 (11) 0.18
Data are number (%) of episodes unless otherwise indicated.
CNS: central nervous system, n: number of episodes in analysis, CI: conﬁdence interval, IQR: interquartile range, IE: infective endocarditis.
aOdds ratios for the association between selected variables and CNS involvement in the multivariate analysis. Variables with odds ratios reported were included in the ﬁnal
multivariate logistic regression model.
bOdds ratio presented per 1-year increase in age.
cEach episode can involve >1 valve.
dProsthetic valve, congenital malformations (excluding atrial septal defect), valvular dysfunction, hypertrophic cardiomyopathy.
eImmunosuppressive therapy (10), HIV infection (6), myelodysplastic syndrome (1).
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The mortality rate in our cohort is low for studies on SAE. The
6.1% 30-day mortality and 9.0% in-hospital mortality is much
lower than the in-hospital mortality of 20–46% observed in
previous large studies [5–12]. It is also lower than the 15–25%
usually reported in association with S. aureus bacteraemia in
general [15,16]. The 1-year mortality rate of 20% is also
considerably lower than the 35–44% found in most other re-
ports [9,10,17,18]. The low case fatality rate in Stockholm can,
to an extent, be explained by the setting and characteristics of
the included SAE patients. The high proportion of patients with
IVDU probably contributes, because they are generally younger
and more often have the milder right-sided IE. The median age
of patients in our study and the percentage with right-sided IE
are, however, similar to that seen in most previous studies
[5–7,9,12], and the mortality (17%) among non-addicts with
left-sided disease is also relatively low. The low proportion of
nosocomial and healthcare-associated cases, with low preva-
lence of comorbidities, may contribute because nosocomial IE
has been associated by some with worse outcome than
community-acquired episodes [6,19]. The low rate of
methicillin-resistant S. aureus could also play a role because
methicillin-resistant S. aureus bacteraemia has been associated
with higher mortality than methicillin-sensitive S. aureus bac-
teraemia [16,20]. Referral bias is not likely to have had a major
inﬂuence on the case fatality ratio in our study, because our
hospital has treated the majority of SAE patients in Stockholm
during the entire period. Finally, one may speculate that high
awareness of IE among physicians could lead to a high number
of early and mild cases being diagnosed. This is, however,
difﬁcult to conﬁrm.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectAge has previously been shown to be independently associ-
ated with mortality in SAE, and has been the most consistent and
strongest predictor ofmortality in S. aureus bacteraemia [5,6,16].
We have no explanation for the higher mortality in females than
in males, but a similar trend has occasionally been seen, both in
SAE and S. aureus bacteraemia [8,16,21]. More detailed data on
disease severity on admission, symptom duration and timing of
diagnosis and treatment are needed for such analysis.
CNS complications
We noted a lower rate (12%) of CNS involvement than the
15–35% generally reported in SAE [5–10]. A high proportion
of right-sided disease and a low cerebral imaging frequency,
however, can contribute to low rates of observed CNS com-
plications. Mitral valve involvement was an independent pre-
dictor of CNS complications. This has been described in
previous studies on IE in general [22,23]. Lower age has also
earlier been independently associated with increased risk of
CNS events in IE, as we noted among our SAE patients
[22,24,25]. Less pronounced inﬂammatory responses, and
fewer and smaller vegetations in elderly compared with
younger patients have been proposed as explanations. It may,
however, be that CNS events are simply under-diagnosed in the
older population because of more unspeciﬁc symptoms and
signs [22,24,25]. Under-diagnosis might also explain the asso-
ciation noted between IVDU and having a lower risk of CNS
complications, but symptom duration at diagnosis or a different
IE pathogenesis in this group could play a role. Vegetation size
has previously been found to be a predictor of cerebral
embolization [22–24], but this could not be analysed because of
inconsistently registered information in our records.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 772–778
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The cardiac surgery frequency was 15% in our SAE cases,
increasing to 24% among our left-sided cases. This ﬁgure is
lower than the 20–45% usually reported in association with
SAE [5–7,9,10,12], but despite this, a favourable outcome was
observed. Similar or even lower rates of valvular surgery were,
however, reported from the 1980s [8,11]. Severe valvular
insufﬁciency and myocardial abscesses are recognized in-
dications for surgery [26,27]. Admission to intensive care is
related to disease severity, whereas higher age and nosocomial
infections are in general associated with more frequent
comorbidities. Furthermore, IVDU is a risk to acquiring a new
IE, and drug users are often regarded as less compliant with
treatments [28,29]. These factors all seem to inﬂuence the
decision to perform surgery.
Incidence
The calculated SAE incidence in Stockholm County of
1.56/100 000 adult inhabitants per year can be compared with
0.2–1.6 SAE/100 000 person-years reported in previous
population-based studies on IE [2,4]. As SAE in Stockholm may
be treated outside the Department of ID at Karolinska Uni-
versity Hospital, the incidence rate presented should be
regarded as a minimum and the actual incidence is likely to be
somewhat higher. The high incidence observed could possibly
be inﬂuenced by Stockholm being an urban area leading to a
high prevalence of IVDU, or other population risk factors. The
diagnosis of IE is dependent on echocardiography and blood
cultures, so the high SAE incidence observed could merely, at
least in part, reﬂect optimal diagnostic procedures and a high
awareness of IE.
We found that the SAE incidence increased over time. A
similar trend has been reported from the USA [1]. As no
change in referral practices from other hospitals occurred
during the study period this does not explain the increase in
incidence. It may in part be due to changes in the at-risk pop-
ulation with an increasing number of people who inject drugs,
more frequent invasive procedures, and an older population
[30], or it might reﬂect a change in diagnostic capabilities and
frequency.
The study has several limitations. The features and outcome
of SAE in a speciﬁc urban population may not apply to pop-
ulations in other settings. Second, although our department
treats a majority of all SAE cases in the county, the study is
based on an experience in a single centre rather than being
population based. A selection and referral bias might therefore
have caused an under-representation of nosocomial cases.
Finally, the study is retrospective and relevant data might have
been missed because they are not always documented in
medical records. The large number of patients included, theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyhigh availability of medical records, and that the study was
performed in a deﬁned geographical area at a single site, on the
other hand, strengthen the validity of our ﬁndings.
To conclude, in this large study on SAE in Stockholm we
found a low mortality, low rate of CNS complications and a low
valvular heart surgery frequency, but a high and increasing
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